Myeloid Dysregulation in a Human Induced Pluripotent Stem Cell Model of PTPN11-Associated Juvenile Myelomonocytic Leukemia

Cell Reports

Volumn 13, Issue 3, 2015, Pages 504-515

  Mulero Navarro, Sonia ^a   Sevilla, Ana ^a   Roman, Angel C ^b   Lee, Dung Fang ^a   D'Souza, Sunita L ^a   Pardo, Sherly ^c   Riess, Ilan ^d   Su, Jie ^a   Cohen, Ninette ^a   Schaniel, Christoph ^a   Rodriguez, Nelson A ^a   Baccarini, Alessia ^a   Brown, Brian D ^a   Cavé, Hélène ^e,f   Caye, Aurélie ^e,f   Strullu, Marion ^e,f   Yalcin, Safak ^g   Park, Christopher Y ^g   Dhandapany, Perundurai S ^a   Yongchao, Ge ^a   Edelmann, Lisa ^a   Bahieg, Sawsan ^a   Raynal, Patrick ^h   Flex, Elisabetta ⁱ   Tartaglia, Marco ^i,j   Moore, Kateri A ^a   Lemischka, Ihor R ^a   Gelb, Bruce D ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b INSTITUTO CAJAL   (Spain)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f INSERM   (France)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h UNIVERSITÉ PAUL SABATIER   (France)

ⁱ ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^j BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 15A; MICRORNA 223; PROTEIN TYROSINE PHOSPHATASE SHP 2; STAT5 PROTEIN; CD33 ANTIGEN; MICRORNA; MIRN15 MICRORNA, HUMAN; MIRN223 MICRORNA, HUMAN; PTPN11 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BONE MARROW CELL; BONE MARROW DERIVED MONONUCLEAR CELL; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SELECTION; FLOW CYTOMETRY; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENOTYPE; HEK293 CELL LINE; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; JUVENILE MYELOMONOCYTIC LEUKEMIA; MYELOPOIESIS; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PTPN11 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UPREGULATION; CELL CULTURE; CYTOLOGY; GENETICS; INDUCED PLURIPOTENT STEM CELL; METABOLISM; MUTATION; PATHOLOGY;

CELLS, CULTURED; HEK293 CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; MICRORNAS; MUTATION; MYELOID CELLS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; SIALIC ACID BINDING IG-LIKE LECTIN 3; UP-REGULATION;

EID: 84944674356     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.019     Document Type: Article

References (24)

1. Araki T., Mohi M.G., Ismat F.A., Bronson R.T., Williams I.R., Kutok J.L., Yang W., Pao L.I., Gilliland D.G., Epstein J.A., Neel B.G. Mouse model of Noonan syndrome reveals cell type- and gene dosage-dependent effects of Ptpn11 mutation. Nat. Med. 2004, 10:849-857.
2. Baccarini A., Chauhan H., Gardner T.J., Jayaprakash A.D., Sachidanandam R., Brown B.D. Kinetic analysis reveals the fate of a microRNA following target regulation in mammalian cells. Curr. Biol. 2011, 21:369-376.
3. Carvajal-Vergara X., Sevilla A., D'Souza S.L., Ang Y.S., Schaniel C., Lee D.F., Yang L., Kaplan A.D., Adler E.D., Rozov R., et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010, 465:808-812.
4. Chan R.J., Leedy M.B., Munugalavadla V., Voorhorst C.S., Li Y., Yu M., Kapur R. Human somatic PTPN11 mutations induce hematopoietic-cell hypersensitivity to granulocyte-macrophage colony-stimulating factor. Blood 2005, 105:3737-3742.
5. Chen C.Z., Li L., Lodish H.F., Bartel D.P. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004, 303:83-86.
6. Chen C., Ridzon D.A., Broomer A.J., Zhou Z., Lee D.H., Nguyen J.T., Barbisin M., Xu N.L., Mahuvakar V.R., Andersen M.R., et al. Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res. 2005, 33:e179.
7. Fragale A., Tartaglia M., Wu J., Gelb B.D. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation. Hum. Mutat. 2004, 23:267-277.
8. Gandre-Babbe S., Paluru P., Aribeana C., Chou S.T., Bresolin S., Lu L., Sullivan S.K., Tasian S.K., Weng J., Favre H., et al. Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood 2013, 121:4925-4929.
9. Grigoriadis A.E., Kennedy M., Bozec A., Brunton F., Stenbeck G., Park I.H., Wagner E.F., Keller G.M. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. Blood 2010, 115:2769-2776.
10. Kennedy M., D'Souza S.L., Lynch-Kattman M., Schwantz S., Keller G. Development of the hemangioblast defines the onset of hematopoiesis in human ES cell differentiation cultures. Blood 2007, 109:2679-2687.
11. Kotecha N., Flores N.J., Irish J.M., Simonds E.F., Sakai D.S., Archambeault S., Diaz-Flores E., Coram M., Shannon K.M., Nolan G.P., Loh M.L. Single-cell profiling identifies aberrant STAT5 activation in myeloid malignancies with specific clinical and biologic correlates. Cancer Cell 2008, 14:335-343.
12. Kotini A.G., Chang C.J., Boussaad I., Delrow J.J., Dolezal E.K., Nagulapally A.B., Perna F., Fishbein G.A., Klimek V.M., Hawkins R.D., et al. Functional analysis of a chromosomal deletion associated with myelodysplastic syndromes using isogenic human induced pluripotent stem cells. Nat. Biotechnol. 2015, 33:646-655.
13. Mian Y.A., Zeleznik-Le N.J. MicroRNAs in leukemias: emerging diagnostic tools and therapeutic targets. Curr. Drug Targets 2010, 11:801-811.
14. Mohi M.G., Williams I.R., Dearolf C.R., Chan G., Kutok J.L., Cohen S., Morgan K., Boulton C., Shigematsu H., Keilhack H., et al. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 2005, 7:179-191.
15. Mullokandov G., Baccarini A., Ruzo A., Jayaprakash A.D., Tung N., Israelow B., Evans M.J., Sachidanandam R., Brown B.D. High-throughput assessment of microRNA activity and function using microRNA sensor and decoy libraries. Nat. Methods 2012, 9:840-846.
16. Nissen-Druey C., Tichelli A., Meyer-Monard S. Human hematopoietic colonies in health and disease. Acta Haematol. 2005, 113:5-96.
17. Pérez B., Mechinaud F., Galambrun C., Ben Romdhane N., Isidor B., Philip N., Derain-Court J., Cassinat B., Lachenaud J., Kaltenbach S., et al. Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemia. J. Med. Genet. 2010, 47:686-691.
18. Ramkissoon S.H., Mainwaring L.A., Ogasawara Y., Keyvanfar K., McCoy J.P., Sloand E.M., Kajigaya S., Young N.S. Hematopoietic-specific microRNA expression in human cells. Leuk. Res. 2006, 30:643-647.
19. Sun W., Shen W., Yang S., Hu F., Li H., Zhu T.H. miR-223 and miR-142 attenuate hematopoietic cell proliferation, and miR-223 positively regulates miR-142 through LMO2 isoforms and CEBP-β. Cell Res. 2010, 20:1158-1169.
20. Takahashi K., Tanabe K., Ohnuki M., Narita M., Ichisaka T., Tomoda K., Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007, 131:861-872.
21. Tartaglia M., Gelb B.G. RAS signaling defects and Noonan syndrome. Inborn Errors of Development: The Molecular Basis of Clinical Disorders of Morphogenesis 2008, 620-631. Oxford University Press. C.J. Epstein, R.P. Erickson, A.J. Wynshaw-Boris (Eds.).
22. Vasilatou D., Papageorgiou S., Pappa V., Papageorgiou E., Dervenoulas J. The role of microRNAs in normal and malignant hematopoiesis. Eur. J. Haematol. 2010, 84:1-16.
23. Yoshida N., Yagasaki H., Xu Y., Matsuda K., Yoshimi A., Takahashi Y., Hama A., Nishio N., Muramatsu H., Watanabe N., et al. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatr. Res. 2009, 65:334-340.
24. Yoshida N., Doisaki S., Kojima S. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations. Paediatr. Drugs 2012, 14:157-163.